Celcuity (NASDAQ:CELC) Sets New 12-Month High – Here’s What Happened

24 Apr 2026, 09:14 by Scott Moore · The Cerbat Gem

Celcuity, Inc. (NASDAQ:CELC – Get Free Report) shares reached a new 52-week high on Wednesday . The stock traded as high as $128.28 and last traded at $123.0530, with a volume of 105409 shares traded. The stock had previously closed at $126.07.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Celcuity in a report on Monday. Wolfe Research reiterated an “outperform” rating and set a $110.00 price target on shares of Celcuity in a report on Thursday, March 12th. Needham & Company LLC reiterated a “buy” rating and issued a $122.00 price objective on shares of Celcuity in a report on Thursday, March 26th. Stifel Nicolaus upped their target price on Celcuity from $115.00 to $125.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. Finally, Wall Street Zen raised Celcuity from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $109.88.

Read Our Latest Stock Analysis on CELC

Celcuity Price Performance

The company has a market cap of $5.49 billion, a P/E ratio of -29.96 and a beta of 0.41. The stock has a 50-day simple moving average of $112.97 and a 200 day simple moving average of $99.33. The company has a debt-to-equity ratio of 3.20, a quick ratio of 10.55 and a current ratio of 10.55.

Celcuity (NASDAQ:CELC – Get Free Report) last released its quarterly earnings data on Wednesday, March 25th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.09. On average, equities analysts expect that Celcuity, Inc. will post -3.97 EPS for the current year.

Insider Transactions at Celcuity

In other news, Director David Dalvey sold 20,000 shares of Celcuity stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $120.03, for a total transaction of $2,400,600.00. Following the sale, the director directly owned 90,000 shares in the company, valued at approximately $10,802,700. The trade was a 18.18% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Richard E. Buller sold 3,000 shares of the stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $110.27, for a total transaction of $330,810.00. Following the completion of the transaction, the director directly owned 6,760 shares of the company’s stock, valued at $745,425.20. This trade represents a 30.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.33% of the stock is currently owned by company insiders.

Institutional Trading of Celcuity

Large investors have recently bought and sold shares of the stock. Ogorek Anthony Joseph NY ADV acquired a new position in Celcuity during the third quarter worth $27,000. EverSource Wealth Advisors LLC grew its holdings in shares of Celcuity by 1,329.2% in the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock worth $34,000 after purchasing an additional 319 shares during the last quarter. US Bancorp DE increased its position in shares of Celcuity by 25.4% during the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after purchasing an additional 143 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of Celcuity by 78.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock worth $35,000 after purchasing an additional 1,167 shares in the last quarter. Finally, Meeder Asset Management Inc. bought a new position in Celcuity during the 4th quarter valued at about $42,000. 63.33% of the stock is currently owned by institutional investors.

Celcuity Company Profile

(Get Free Report)

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.